Application Filed in Denmark for North American Vaccine's DTaP-IPV Vaccine.

BELTSVILLE, Md.--(BUSINESS WIRE)--Oct. 19, 1995--North American Vaccine (AMEX:NVX) announced today that a product registration application for a combined diphtheria, tetanus, pertussis (whooping cough) and enhanced inactivated polio ("DTaP-IPV") vaccine has been filed in Denmark. The application, filed by Statens Seruminstitut (SSI), seeks regulatory approval of the DTaP-IPV vaccine for all primary and booster doses for infants and children. There is no acellular pertussis vaccine licensed for use in Denmark and, if approved, this could be the first DTaP-IPV vaccine licensed for use in Europe.

The filing of this application follows successful completion of a clinical evaluation of the vaccine in Denmark. The combination DTaP-IPV vaccine was developed by the Company and SSI under a collaboration agreement. The current immunization practice in Denmark is to provide the polio vaccine in combination with diphtheria and tetanus as a combined DT-IPV vaccine with a whole-cell pertussis vaccine being administered separately. The combined DTaP-IPV vaccine, if approved, will introduce immunization against whooping cough with an acellular pertussis vaccine into Denmark for the first time and will replace the currently used DT-IPV vaccine. An additional and significant benefit of the combined DTaP-IPV vaccine is that it will reduce by one- half the number of vaccinations given to infants and children.

North American Vaccine, Inc., both directly and through its subsidiaries, is engaged in the research, development and production of vaccines to prevent human infectious diseases.

CONTACT: North American Vaccine, Inc.

Thomas Salyers, 202/835-8884